Neurocrine Biosciences Inc.'s (NASDAQ:NBIX) board director, Leslie V. Norwalk, completed a significant sale of company stock on May 12, 2026. Ms. Norwalk disposed of 3,810 shares of Neurocrine's common stock, resulting in total proceeds amounting to $590,601.
The details of the disposition indicate that the shares were sold at prices ranging between $155.00 and $155.0550 per share. Critically, this sale was managed through a broker following a Rule 10b5-1 trading plan. This specific plan was adopted and became effective on September 15, 2025. The company's policy governing reporting persons dictates that once such a 10b5-1 trading plan is established, it cannot be amended or modified by the individual.
This insider selling activity takes place against a backdrop of positive market performance for NBIX. Currently, the stock is trading at $159.05, approaching its 52-week high of $161.76. Furthermore, an analysis provided by InvestingPro suggests that the stock may be undervalued at current levels, noting a PEG ratio of just 0.18. The platform also offers additional insights for NBIX investors, including analyses of profitability trends and analyst revisions.
The context surrounding this transaction is further illuminated by Neurocrine Biosciences' recent financial disclosures. For the first quarter of 2026, the company delivered a robust performance, exceeding both earnings and revenue projections. The reported earnings per share (EPS) reached $1.94. This figure significantly surpassed the anticipated EPS of $1.17, representing an impressive earnings surprise of 65.81%.
In terms of top-line growth, Neurocrine Biosciences announced total revenue of $811 million. This amount was higher than the forecasted figure of $766.85 million. These results collectively point toward a strong operational start for the company during the year. The positive financial report prompted a noticeable increase in the value of the company's stock, with investors and analysts closely monitoring these developments. Such attention reflects confidence regarding Neurocrine Biosciences’ ongoing financial health and its demonstrated ability to outperform market expectations.
Following this specific transaction on May 12, 2026, Leslie V. Norwalk maintained a direct holding of 2,429 shares of Neurocrine Biosciences common stock.
Risks
- The sale represents an insider disposition, which can sometimes signal internal adjustments in confidence or perception.
- Market reactions to strong earnings reports can create volatility, requiring continuous monitoring from investors and analysts.
- Future financial performance hinges on maintaining the momentum established by the Q1 2026 results and meeting continued market expectations.
More from Insider Trading
Risks
- The sale represents an insider disposition, which can sometimes signal internal adjustments in confidence or perception.
- Market reactions to strong earnings reports can create volatility, requiring continuous monitoring from investors and analysts.
- Future financial performance hinges on maintaining the momentum established by the Q1 2026 results and meeting continued market expectations.